The last couple weeks on the market have been punishing for formerly highflying drug and device stocks. But one common side effect of lower valuations is more buyouts, which fanned a fair bit of Wall Street chatter and speculation this week. Here are the three getting the most attention. The most likely to be true: on Friday afternoon, Bloomberg reported that Baxalta (BXLT), the recently spun-off biopharma arm of Baxter International (BAX), is
Splunk pleasantly surprised Wall Street late Thursday, posting fiscal Q2 earnings a penny ahead of analyst estimates and revenue that soundly beat forecasts, and it hiked its sales outlook for the year. The maker of machine-to-machine data analytics software reported earnings per share minus items of 3 cents, up from a penny in the year-earlier quarter and ahead of the 2 cents expected by analysts polled by Thomson Reuters. Revenue for the quarter
Worries about future growth weighed on Workday stock, even as the company continued an estimate-beating streak Wednesday with second-quarter earnings that on an adjusted basis turned the corner into profitability. The provider of cloud-based finance and human resources software delivered a 2-cent per share profit excluding items for the period ended July 31. That’s a swing from an 11-cent loss a year ago and beats the 6-cent loss expected, on